ライフサイエンスコーパス: glycated hemoglobin

1 holesterol, high C-reactive protein and high glycated hemoglobin).

2 e foreclosure rate per census-block group on glycated hemoglobin.

3 block group in the prior year and changes in glycated hemoglobin.

4 een the study groups were seen for change in glycated hemoglobin.

5 tion to determine levels of CRP, lipids, and glycated hemoglobin.

6 ng glucose and postload glucose but not with glycated hemoglobin.

7 in cholesterol, systolic blood pressure, and glycated hemoglobin.

8 ith adjustment for all covariates as well as glycated hemoglobin.

9 s-related traits such as fasting glucose and glycated hemoglobin.

10 f signals while varying concentration of the glycated hemoglobin.

11 o five subfractions, four of which contained glycated hemoglobins.

12 points, P<0.001) and had similar control of glycated hemoglobin (0.3 percentage points, P=0.63).

13 (-22.5 vs. -9.9%, p = 0.05), and decrease in glycated hemoglobin (-0.6% vs. -0.3%, p = 0.01).

14 d 10.2 percentage points, respectively), and glycated hemoglobin (10.1 percentage points and 9.4 perc

15 of 1.42 (0.69-2.92) and 2.91 (1.19-7.11) for glycated hemoglobin 5.7-<6.5% and >/=6.5%, respectively,

16 of 1.12 (0.94-1.34) and 1.39 (1.04-1.85) for glycated hemoglobin 5.7-6.4% and >/=6.5%, respectively,

17 omol/L [IQR, 72-89 micromol/L], P = .61) and glycated hemoglobin (5.9% [IQR, 5.6%-6.1%] vs 5.9% [IQR,

18 97 individuals >=40 and <=80 years old with glycated hemoglobin 6.5% to 10.0%, known coronary artery

19 ss index (47.6+/-9.3 to 36.7+/-7; P<0.0001), glycated hemoglobin (6.7+/-1.5 to 5.8+/-0.6; P<0.0001),

20 Thirteen people with T2DM (glycated hemoglobin, 6.9+/-1.0%) and 12 age-matched heal

21 y; median (IQR), 10 (5-9) y of T2D duration; glycated hemoglobin 7.0% +/- 0.8%; body mass index (in k

22 an age, 64.0 years; 2414 [39.9%] women; mean glycated hemoglobin, 7.2%; median duration of diabetes,

23 (excluding gestational diabetes mellitus) or glycated hemoglobin A(1c) of 6.5% or greater.

24 fication by sex, history of ischemic stroke, glycated hemoglobin A(1c), body mass index, blood pressu

25 llected at each visit for the assay of serum glycated hemoglobin A1c (A1c), hsCRP, d-8-iso, MMP-2, an

26 g plasma glucose >/=200 mg/dl (11.1 mmol/l), glycated hemoglobin A1c (HbA1c) >6.5%, self-reported phy

27 nfidence intervals (CIs) were calculated for glycated hemoglobin A1c (HbA1c), fasting plasma glucose

28 se [FCG] level, 2-hour CG [2-hCG] level, and glycated hemoglobin A1c [HbA1c] level) at enrollment, an

29 agnosis, sex, race/ethnicity, net worth, and glycated hemoglobin A1c fraction (HbA1c).

30 While adjusting for duration of diabetes, glycated hemoglobin A1c level, and other factors, we fou

31 Glycated hemoglobin A1c levels improved to 7.0% [6.4%-7.

32 The mean (SD) glycated hemoglobin A1c of the 50 patients (26 men and 2

33 ciation of baseline waist circumference with glycated hemoglobin A1c reduction is likely due to selec

34 The only significant predictor of glycated hemoglobin A1c reduction was waist circumferenc

35 are well-adhered to, whereas guidelines for glycated hemoglobin A1c testing for type 2 diabetes mell

36 s largely determined by assessment of HbA1c (glycated hemoglobin A1c) levels, which poorly reflects d

37 Tested as continuous variables, glycated hemoglobin A1C, but neither body mass index nor

38 Weight, BMI, glycated hemoglobin A1c, fasting glucose, and insulin we

39 We collected data on histories of patients' glycated hemoglobin A1c, hypertension, hyperlipidemia, s

40 tions, pain (numeric rating scale), level of glycated hemoglobin A1c, level of C-reactive protein, bo

41 Complete remission was defined as glycated hemoglobin (A1C) less than 6% and fasting blood

42 sted difference, 1.0 percentage points), and glycated hemoglobin (adjusted difference, 3.4 percentage

43 ysis (OCT) over a 4-y period, independent of glycated hemoglobin, age, and sex.

44 syndrome (69.2 vs. 51.9%), fast glycemia and glycated hemoglobin, albuminuria, triglycerides and uric

45 s there exists a direct relationship between glycated hemoglobin and cardiovascular disease (CVD), cl

46 y is to investigate the relationship between glycated hemoglobin and circulating levels of interleuki

47 In contrast, glycated hemoglobin and death from any cause were found

48 We compared the prognostic value of glycated hemoglobin and fasting glucose for identifying

49 All participants were screened for DM using glycated hemoglobin and fasting plasma glucose at TB tre

50 rvention also produced greater reductions in glycated hemoglobin and greater initial improvements in

51 erum concentrations of metabolic parameters (glycated hemoglobin and low-density lipoprotein), inflam

52 abetes Association diagnostic cut points for glycated hemoglobin and microvascular outcomes (chronic

53 ic red blood cells correlates with levels of glycated hemoglobin and that the mechanical properties o

54 inal pro-B-type natriuretic peptide), HbA1C (glycated hemoglobin), and systolic blood pressure were o

55 cholesterol, triglycerides, blood pressure, glycated hemoglobin, and fasting glucose and report the

56 ar reductions in insulin, insulin C-peptide, glycated hemoglobin, and homeostasis model assessment of

57 measured in urine, with diabetes prevalence, glycated hemoglobin, and insulin resistance in American

58 ymptoms and changes in the levels of lipids, glycated hemoglobin, and prolactin were similar in the t

59 ats maintained in poor glycemic control (PC, glycated hemoglobin approximately 11%) or in good glycem

60 mately 11%) or in good glycemic control (GC, glycated hemoglobin approximately 6%) for 6 months, or i

61 rs are modestly effective in reducing HbA1c (glycated hemoglobin) ( approximately 0.5%) and while the

62 ta add to the evidence supporting the use of glycated hemoglobin as a diagnostic test for diabetes.

63 of Germany or Austria), body mass index, and glycated hemoglobin as covariates were used to account f

64 iculated thrombocytosis that correlates with glycated hemoglobin as well as increased plasma S100A8/A

65 e variation, complicates the clinical use of glycated hemoglobin assays for the diagnosis and managem

66 Mean glycated hemoglobin at baseline was similar in both grou

67 ing age, absence of epiretinal membrane, and glycated hemoglobin below 9 as predictive of DR ultra-re

68 ears after baseline on the basis of either a glycated hemoglobin concentration of at least 6.5% or us

69 studies that have demonstrated reductions in glycated hemoglobin concentration.

70 hod for measuring the hemoglobin A1c (HbA1c, glycated hemoglobin) concentration, hemoglobin (Hb) conc

71 moglobin glycation index (HGI), a measure of glycated hemoglobin controlled for blood glucose variati

72 ng an extended interval of separation of the glycated hemoglobin curves (hazard ratio, 0.83; 95% CI,

73 ed 1791 participants), the separation of the glycated hemoglobin curves between the intensive-therapy

74 nly during the prolonged period in which the glycated hemoglobin curves were separated.

75 se of new 2010 American Diabetes Association glycated hemoglobin cut points for the diagnosis of diab

76 s improved, for example, fasting glucose and glycated hemoglobin decreased from 6.1 to 5.4 mmol/mol a

77 Glycated hemoglobin decreased significantly from 8.2 +/-

78 liflozin group than in the placebo group for glycated hemoglobin (difference, -0.46 percentage points

79 e intervention group had significantly lower glycated hemoglobin, fasting plasma glucose, plaque inde

80 The primary endpoint was change in glycated hemoglobin from baseline.

81 poor glycemic control (PC, approximately 12% glycated hemoglobin [GHb]) for 3 months followed by in g

82 body mass index (BMI; in kg/m(2)) of 32, and glycated hemoglobin (Hb A(1c)) of 5.9%.

83 Improved glycated hemoglobin (Hb A1c) delays the progression of m

84 oad glucose (PG), 2-h postload insulin (PI), glycated hemoglobin (Hb A1c), and homeostasis model asse

85 Glycated hemoglobin (HbA(1c)) is an important measure of

86 Glycated hemoglobin (HbA(1c)) values are higher in Afric

87 08) while controlling for age, sex, baseline glycated hemoglobin (HbA(1c)), baseline CMT, baseline VA

88 es diagnosis, serum fasting glucose (FG) and glycated hemoglobin (HbA(1c)), were estimated to be 51-6

89 omes, including height, weight, and level of glycated hemoglobin (HbA(1c)).

90 s: colorectal screening rates; diabetes with glycated hemoglobin (HbA1c level) less than 9.0%; diabet

91 om among 321 people with type 2 diabetes and glycated hemoglobin (HbA1c) >58 mmol/mol.

92 ype 2 diabetes were recruited: subjects with glycated hemoglobin (HbA1c) </=7% and subjects with HbA1

93 ; betaPFOA=1.71 pM; 95% CI: 0.72, 2.71), and glycated hemoglobin (HbA1c) (betaPFOS=0.03%; 95% CI: 0.0

94 ) concentration (-37.0 mg/dL; P < 0.001) and glycated hemoglobin (HbA1c) [-0.97% (-10.6 mmol/mol); P

95 nt increases in hippocampal FC, decreases in glycated hemoglobin (HbA1c) and body fat, and increases

96 We examined the association between baseline glycated hemoglobin (HbA1c) and high-sensitivity cardiac

97 A 66-year-old man affected by DME, with glycated hemoglobin (HbA1c) at 6.9%, refractory to laser

98 a significant difference in postintervention glycated hemoglobin (HbA1c) between the arms (P = 0.007)

99 ulinemia, decreased C-peptide, and increased glycated hemoglobin (HbA1c) compared with sham-operated

100 d the association between food label use and glycated hemoglobin (HbA1c) concentrations.

101 After 12 months, glycated hemoglobin (HbA1c) decreased from 10.3+/-2.4% t

102 In recent years, glycated hemoglobin (HbA1c) has been increasingly accept

103 has been developed for the determination of glycated hemoglobin (HbA1c) in human blood samples.

104 The level of Glycated hemoglobin (HbA1c) is accordingly examined for

105 Glycated hemoglobin (HbA1c) is one of the most important

106 Glycated hemoglobin (HbA1c) is used to diagnose type 2 d

107 lycemia from birth, resulting in an elevated glycated hemoglobin (HbA1c) level that mimics recommende

108 ex, waist circumference, fat percentage, and glycated hemoglobin (HbA1c) level were recorded chairsid

109 n leakage area at month 36 (P = 0.0137), and glycated hemoglobin (HbA1c) levels at month 36 (P = 0.00

110 ed the association between periodontitis and glycated hemoglobin (HbA1c) levels in individuals withou

111 (20-50 U) and metformin (>/=1500 mg/d) with glycated hemoglobin (HbA1c) levels of 7% to 10% and a bo

112 nfluence of periodontal status on changes of glycated hemoglobin (HbA1c) levels of patients with type

113 igated OCT-A parameters with DM duration and glycated hemoglobin (HbA1c) levels were evaluated among

114 Glycated hemoglobin (HbA1c) levels were measured at base

115 Glycated hemoglobin (HbA1c) levels were measured, and pr

116 2 spectral domain OCT (SD-OCT) tests, and 2 glycated hemoglobin (HbA1c) measures over time with a mi

117 DM prevalence was estimated using laboratory glycated hemoglobin (HbA1c) or fasting plasma glucose in

118 Glycated proteins, such as glycated hemoglobin (HbA1c) or glycated albumin (GA) in

119 hievement of good glycemic control, of which glycated hemoglobin (HbA1c) remains the standard clinica

120 An immunoassay for detection of glycated hemoglobin (HbA1c) that can reveal a patient's

121 in or loss and glycemic control (assessed by glycated hemoglobin (HbA1c) values) in patients from the

122 In multivariable analyses, glycated hemoglobin (HbA1c) was inversely associated wit

123 Higher levels of glycated hemoglobin (HbA1c) were associated with all-cau

124 rmined for fasting glucose, fasting insulin, glycated hemoglobin (HbA1c), and homeostasis model asses

125 glucose, C-reactive protein, triglycerides, glycated hemoglobin (HbA1c), and total, low-density lipo

126 tion of high- compared with low-fat dairy on glycated hemoglobin (HbA1c), body weight, and cardiovasc

127 The relationship between delayed GE and glycated hemoglobin (HbA1c), complications of DM, and ga

128 eplacement of other sugars and its effect on glycated hemoglobin (HbA1c), fasting blood glucose, insu

129 agnostic accuracies of random blood glucose, glycated hemoglobin (HBA1c), fructosamine, and Homeostas

130 glycemia (diabetes status, fasting glucose, glycated hemoglobin (HbA1c), fructosamine, glycated albu

131 triacylglycerol (TG), fasting glucose (FG), glycated hemoglobin (HbA1c), insulin resistance (HOMA-IR

132 and at follow-up, was associated with higher glycated hemoglobin (HbA1c), insulin, HOMA-IR, triglycer

133 ent of glycated blood proteins, particularly glycated hemoglobin (HbA1c), is an important diagnostic

134 Blood glycated hemoglobin (HbA1c), reflecting the average bloo

135 ed with the diabetes GRS on fasting insulin, glycated hemoglobin (HbA1c), the homeostasis model asses

136 Measurement of glycated hemoglobin (HbA1c), the most widely accepted in

137 blood pressure (BP), fasting blood glucose, glycated hemoglobin (HbA1c), triglyceride levels, trigly

138 led trials (RCTs) that assessed the outcomes glycated hemoglobin (HbA1c), weight, body mass index (BM

139 sensor was developed for the recognition of glycated hemoglobin (HbA1c).

140 dy mass index, random blood sugar (RBS), and glycated hemoglobin (HbA1c).

141 trol was assessed according to percentage of glycated hemoglobin (HbA1c).

142 body mass index (in kg/m(2)): 34.6 +/- 4.3; glycated hemoglobin (HbA1c): 7.3 +/- 1.1%; duration of d

143 n [n = 136; mean +/- SD age: 12.8 +/- 2.6 y; glycated hemoglobin (HbA1c): 8.1% +/- 1.0%; 69.1% using

144 .7%) was associated with a reduction in mean glycated hemoglobin (HbA1c, -1.3 +/- 1.8%, P < 0.001), f

145 d by measurement of the cutoff ratio between glycated hemoglobins (HbA1c) and total hemoglobin (Hb),

146 ol/L, 2-hr plasma glucose >/=11.1 mmol/L, or glycated hemoglobin [HbA1c] >/=6.5%) was detected in 46%

147 8 of whom had poor glycemic control (average glycated hemoglobin [HbA1c] >/=8% during the year) while

148 tensive glycemic control in type 2 diabetes (glycated hemoglobin [HbA1c] level <7%) is an established

149 cose [RBG], fasting blood glucose [FBG], and glycated hemoglobin [HbA1c]) and survival in all lung tr

150 cant between-group differences were found in glycated hemoglobin, HDL-cholesterol, or triglyceride co

151 In 2006, 56% of incident cases had a glycated hemoglobin (hemoglobin A1c) test as one of the

152 justment for metabolic biomarkers, including glycated hemoglobin, high-density lipoprotein cholestero

153 There was no change in glycated hemoglobin in either group: mean, 7.4 (95% CI,

154 h both incidence of T2D and increased plasma glycated hemoglobin in individuals without T2D, providin

155 and with low HDL concentrations and elevated glycated hemoglobin in obese and diabetic patients.CCK r

156 We measured glycated hemoglobin in whole-blood samples from 11,092 b

157 Levels of blood glucose/glycated hemoglobin (International Federation of Clinica

158 closures do not affect health in general, 2) glycated hemoglobin is insensitive to local foreclosure

159 rly high-density lipoprotein cholesterol and glycated hemoglobin, led to a greater degree of attenuat

160 For every 1% higher glycated hemoglobin, left ventricular mass was higher by

161 dard therapy or aggressive therapy (targets: glycated hemoglobin level <6.0%, low-density lipoprotein

162 val [CI], 0.8 to 15.0) for glycemic control (glycated hemoglobin level <7.0%), 9.4 percentage points

163 ed optimal diabetes care (n = 448) (targets: glycated hemoglobin level <7.0%, low-density lipoprotein

164 52.5 vs 54.8 years), BMI (45.1 vs 42.6), and glycated hemoglobin level (7.1% vs 7.1%).

165 At 1 year, the baseline mean glycated hemoglobin level (8.3% in the two study groups)

166 At 2 years, the average baseline glycated hemoglobin level (8.65+/-1.45%) had decreased i

167 wer; 95% CI, 24 to 51; P<0.001) and the mean glycated hemoglobin level (difference, -0.3%; 95% CI, -0

168 , 1.02; 95% CI, 1.01-1.04) and knowing one's glycated hemoglobin level (odds ratio, 2.00; 95% CI, 1.3

169 on of T2DM (P = 0.006), a higher presurgical glycated hemoglobin level (P = 0.019), insulin treatment

170 , sulfonylurea) with stable body weight, and glycated hemoglobin level 7.0% to 10.0%.

171 uration of diabetes 34.6 years, and the mean glycated hemoglobin level 8.2%.

172 nd point was the change from baseline in the glycated hemoglobin level after 26 weeks.

173 The mean adjusted difference in glycated hemoglobin level after 6 months was -0.33 perce

174 index greater than the 85th percentile and a glycated hemoglobin level between 7.0 and 11.0% if the p

175 eters) for 84.2% of participants and data on glycated hemoglobin level for 71.3% of participants.

176 os for death from any cause according to the glycated hemoglobin level for patients with diabetes as

177 The primary end point was the change in glycated hemoglobin level from baseline to week 26.

178 of the primary efficacy end point, the mean glycated hemoglobin level had decreased by 0.64 percenta

179 Glycated hemoglobin level had poorer test characteristic

180 The primary end point was a glycated hemoglobin level lower than 7.0% at week 24, wi

181 n, the proportion of patients who achieved a glycated hemoglobin level lower than 7.0% with no severe

182 mg per deciliter [5.6 mmol per liter] and a glycated hemoglobin level of <6.5% in the absence of pha

183 with 4.3% over 3 years among patients with a glycated hemoglobin level of 10%.

184 was 1.0% over 5 years among patients with a glycated hemoglobin level of 6%, as compared with 4.3% o

185 point was the proportion of patients with a glycated hemoglobin level of 6.0% or less 12 months afte

186 The primary outcome was a glycated hemoglobin level of 6.0% or less with or withou

187 The primary end point was a glycated hemoglobin level of 6.0% or less.

188 MI of 35 or more, a BMI of 40 or more, and a glycated hemoglobin level of 6.5% or more were lower in

189 diagnosis of obstructive sleep apnea, with a glycated hemoglobin level of 6.5-8.5%, and an oxygen des

190 ients younger than 55 years of age who had a glycated hemoglobin level of 6.9% or less (</=52 mmol pe

191 ng those younger than 55 years of age with a glycated hemoglobin level of 6.9% or less, as compared w

192 trols were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (</=52 mmol p

193 l study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of

194 story of at least 5 years of diabetes, and a glycated hemoglobin level of 7.0% or more were randomly

195 ol improved in all three groups, with a mean glycated hemoglobin level of 7.5+/-1.8% in the medical-t

196 e was loss of glycemic control, defined as a glycated hemoglobin level of at least 8% for 6 months or

197 , but intensive glucose control, targeting a glycated hemoglobin level of less than 6.5%, did not.

198 t a dose of 1000 mg twice daily) to attain a glycated hemoglobin level of less than 8% and were rando

199 ed hemoglobin level score [calculated as the glycated hemoglobin level plus 4 times the insulin dose]

200 of the patients was 14 to 71 years, and the glycated hemoglobin level ranged from 5.4 to 10.6%.

201 e patient's current state of retinopathy and glycated hemoglobin level reduced the frequency of eye e

202 esponse (defined as an insulin dose-adjusted glycated hemoglobin level score [calculated as the glyca

203 r mean percentage reduction from baseline in glycated hemoglobin level than did patients who received

204 e estimated mean change from baseline in the glycated hemoglobin level was -1.33 percentage points in

205 The mean (SD) glycated hemoglobin level was 7.4% (0.5%).

206 At 24 months, the mean glycated hemoglobin level was 7.5+/-1.2% in each group,

207 similar in the two groups; the mean baseline glycated hemoglobin level was 8.09% in the icodec group

208 iabetes was 16.4 years, and the mean (+/-SD) glycated hemoglobin level was 8.4+/-1.7%; 83.9% of the p

209 s 16.1 years (range, 2-36 years), and median glycated hemoglobin level was 8.8% (IQR, 7.4%-10%).

210 s was 49+/-8 years, 66% were women, the mean glycated hemoglobin level was 9.2+/-1.5%, and the mean B

211 The average glycated hemoglobin level was 9.2+/-1.5%.

212 /-8 years, 68% were women, the mean baseline glycated hemoglobin level was 9.3+/-1.5%, and the mean b

213 hich patients with type 2 diabetes mellitus (glycated hemoglobin level, >=7%), chronic kidney disease

214 ucose load, 140 to 199 mg per deciliter; and glycated hemoglobin level, 5.7 to 6.4%) and no diagnosti

215 type 2 diabetes was inadequately controlled (glycated hemoglobin level, 7.0 to 9.5%) while taking met

216 etes had poor glycemic control (mean [+/-SD] glycated hemoglobin level, 9.0+/-2.4%), and the rates of

217 s >180 mg per deciliter, mean glucose level, glycated hemoglobin level, and percentage of time that t

218 Secondary outcomes included the glycated hemoglobin level, mean daily insulin dose, rate

219 ith placebo did not affect the insulin dose, glycated hemoglobin level, or hypoglycemia rate.

220 itional end points included insulin use, the glycated hemoglobin level, the number of hypoglycemic ev

221 points included the change from baseline in glycated hemoglobin level, weight, systolic blood pressu

222 C-peptide levels, insulin requirements, and glycated hemoglobin level.

223 lycemia, and, in adults, resulted in a lower glycated hemoglobin level.

224 1.13; P = .003) for each unit of increase in glycated hemoglobin level.

225 counting for glycemic control in the form of glycated hemoglobin level.

226 primary safety outcome was the change in the glycated hemoglobin level.

227 y end point was the change from the baseline glycated hemoglobin level.

228 significant difference between the groups in glycated hemoglobin level.

229 e injection-therapy group reached the target glycated hemoglobin level.

230 greater overall 12-month improvement across glycated hemoglobin levels (difference, 0.58%), LDL chol

231 t did not continue after equalization of the glycated hemoglobin levels (hazard ratio, 1.26; 95% CI,

232 f 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean differenc

233 The phenomenon of a discrepancy between glycated hemoglobin levels and other indicators of avera

234 loop group and 23 to the control group); the glycated hemoglobin levels at baseline ranged from 5.7 t

235 The difference in glycated hemoglobin levels between the intensive-therapy

236 ween-group differences in blood pressure and glycated hemoglobin levels during the trial were no long

237 of glucose levels and 10,208 measurements of glycated hemoglobin levels from 2067 participants withou

238 previously been found to reduce glucose and glycated hemoglobin levels in humans.

239 clines in cortisol levels, blood glucose and glycated hemoglobin levels increased soon after treatmen

240 Glycated hemoglobin levels measured by all three primary

241 we observed no significant effect on average glycated hemoglobin levels or on the percentage of parti

242 e fully attenuated after adjustment for mean glycated hemoglobin levels over the entire follow-up.

243 sults show that interindividual variation in glycated hemoglobin levels was evident in diabetes patie

244 Glycated hemoglobin levels were lower with pump therapy

245 Glycated hemoglobin levels were measured using three pri

246 Glycated hemoglobin levels were significantly lower with

247 the greatest degree of improvement (average glycated hemoglobin levels, 7.69+/-0.57% in the medical-

248 erapy resulted in significant improvement in glycated hemoglobin levels, as compared with injection t

249 Secondary outcomes included glycated hemoglobin levels, insulin dose, and body mass

250 Interindividual and ethnic variation in glycated hemoglobin levels, unrelated to blood glucose v

251 al history, antidiabetic medication use, and glycated hemoglobin levels.

252 c blood pressures, and high triglyceride and glycated hemoglobin levels.

253 on self-report or fasting serum glucose and glycated hemoglobin levels.

254 men, C-reactive protein, lipoprotein(a), and glycated hemoglobin levels.

255 progression was also closely related to mean glycated hemoglobin levels.

256 ere among metabolic surgery patients (higher glycated hemoglobin levels; greater percentage of insuli

257 es included blood-pressure, cholesterol, and glycated hemoglobin levels; screening for depression; me

258 cident CKD included BP >140/90 mm Hg, higher glycated hemoglobin, lower baseline eGFR, and higher bas

259 ith type 2 diabetes in good glucose control (glycated hemoglobin < 7.5%) before and after 7 d of a VL

260 For type 2 diabetes (glycated hemoglobin <6.5% without medication), sample-si

261 Glycated hemoglobin measurements were compared in patien

262 amer-based microfluidic system for automatic glycated hemoglobin measurements.

263 ptical coherence tomography, blood pressure, glycated hemoglobin, medications, and changes in such pa

264 /m(2)) of 39.2 (95% CI: 35.2, 43.3) and mean glycated hemoglobin of 5.3% (95% CI: 4.9%, 5.6%), were s

265 Adults with type 2 diabetes, glycated hemoglobin of 6.5% to 8.5%, and elevated cardio

266 How these risks vary with glycated hemoglobin (or hemoglobin A1c [HbA1c]) levels i

267 ion was associated with a higher increase in glycated hemoglobin (P = 0.027).

268 Assessing the types and amounts of glycated hemoglobins present in erythrocytes could provi

269 the intention-to-treat population, the mean glycated hemoglobin profile improved in the intervention

270 ceride/HDL-C ratio (r = 0.16, p = 0.03), and glycated hemoglobin (r = 0.16, p = 0.03) with pioglitazo

271 luble leptin receptor (reduction of 43%) and glycated hemoglobin (reduction of 28%).

272 o a greater improvement in glycemic control [glycated hemoglobin reductions of -0.12% (P = 0.04), -0.

273 positive correlation of chemerin with IL-6, glycated hemoglobin, sampled-site clinical attachment le

274 adjusting for age, waist-to-hip ratio (WHR), glycated hemoglobin, smoking, education, and grip streng

275 The proportion of patients who reached the glycated hemoglobin target (<7%) was greater in the pump

276 x, diabetes, waist/hip ratios, and levels of glycated hemoglobin, the NAFLD activity score was associ

277 We used admission glycated hemoglobin to estimate premorbid baseline blood

278 lar disease (CVD), clinical trials targeting glycated hemoglobin to near-normal levels using intensiv

279 corresponding reduction in the percentage of glycated-hemoglobin to levels similar to lean, healthy m

280 rotein cholesterol (HDL-C) and reductions in glycated hemoglobin, triglycerides, and C-reactive prote

281 meters controlling for sex, body mass index, glycated hemoglobin, use of oral hypoglycemic drugs, and

282 The glycated hemoglobin value at baseline was associated wit

283 mg per deciliter (2.6 mmol per liter), and a glycated hemoglobin value of 9.0% or lower, according to

284 ological factors assessed, insulin index and glycated hemoglobin values explained 15% and 16% of the

285 periodontitis presented higher glycemia and glycated hemoglobin values in contrast to patients with

286 For glycated hemoglobin values of less than 5.0%, 5.0 to les

287 The changes in glycated hemoglobin values were similar in the two group

288 d nocturnal hypoglycemia, without increasing glycated hemoglobin values.

289 mination showed significant improvement when glycated hemoglobin was added to models including fastin

290 Recently, glycated hemoglobin was also recommended for this purpos

291 In the absence of diagnosed diabetes, glycated hemoglobin was cross sectionally associated wit

292 n or albuminuria or blood pressure, although glycated hemoglobin was lowered with both diets.

293 Glycated hemoglobin was recently recommended for use as

294 nity-based population of nondiabetic adults, glycated hemoglobin was similarly associated with a risk

295 diabetes at baseline, clinical categories of glycated hemoglobin were associated with risk of chronic

296 rular basement membrane and higher levels of glycated hemoglobin were independent predictors of progr

297 lar blood glucose levels regardless of which glycated hemoglobins were measured.

298 ignificant thresholds in the associations of glycated hemoglobin with kidney disease risk or retinopa

299 mm Hg; -9.0, -2.7 mm Hg) diets, and reduced glycated hemoglobin with the Mediterranean diet (-0.8 mm

300 e of risk thresholds in the relationships of glycated hemoglobin with these outcomes.